Interestingly, the combination between MCT11-blockade and ICB therapy in adenocarcinoma only moderately improved the cytokine production of TEX cells compared to ICB alone but greatly reduced the tumor burden and improved survival. The gene discussed is SLC16A11; the disease is neoplasm.